Korea United Pharm and UNS Bio said Friday that they had signed a memorandum of understanding with Y-Biologics to develop new antibody-drug conjugate (ADC) anticancer drugs.Through this agreement, the three companies will conduct joint research on developing new ADC anticancer drugs and present a ne
Galderma Korea said Friday that it will launch “Restylane Eyelight,” a new product of its premium hyaluronic acid filler brand Restylane, in June in Korea.Restylane Eyelight features Galderma's proprietary “NASHA” technology, a patented process that enables precise treatment of difficult facial area
OliX Pharmaceuticals’ short interfering ribonucleic acid (siRNA)-based hypertrophic scar treatment OLX10010 (OLX101A) has raised questions in the market due to the omission of certain information, including safety assessments, in the published results of its phase 2a clinical trial.On Wednesday, Oli
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have another immunotherapy option for first-line systemic treatment.The dual immunotherapy of Imfinzi (durvalumab) and Imjudo (tremelimumab) is expected to provide a new a
The clinical significance of the new antibody-drug conjugate (ADC) drug Enhertu (trastuzumab deruxtecan), which was launched by AstraZeneca and Daiichi Sankyo and won health insurance coverage in Korea this month, gained attention among breast cancer specialists at a recent conference in Seoul.A sym
Biotech startups supported by Celltrion through its “open innovation strategy” are nesting in Seoul Biohub.Celltrion said Thursday that it attended the Seoul Biohub Global Center opening ceremony in Dongdaemun-gu, Seoul. Three companies supported by Celltrion—MediMabBio, S&K Therapeutics, and Entero
LG Chem has announced a partnership with EuBiologics to enhance the domestic production capabilities of pediatric vaccines in Korea.The collaboration focuses on developing the hexavalent vaccine LR20062, which is designed to protect against six diseases -- diphtheria, tetanus, pertussis (whooping co
Novartis' angiotensin receptor-neprilysin inhibitor (ARNI) heart failure treatment Entresto (sacubitril/valsartan) has reduced hospitalization rates in patients with newly diagnosed (de novo) heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fract
Moderna and the Korean National Institute for Bioprocessing Research and Training (K-NIBRT) at Yonsei University have signed an agreement to develop mRNA education content and programs, accelerating the full-scale operation of the curriculum.The agreement follows a memorandum of understanding signed
Onconic Therapeutics, a subsidiary of Jeil Pharma Holdings, said it received approval from the Ministry of Food and Drug Safety for Jaqbo (ingredient: Zastaprazan), a drug for the treatment of gastroesophageal reflux disease (GERD) and Korea's 37th domestically developed new drug.Jaqbo represents a
Daewoong Pharmaceutical said Thursday that Fexuclue's prescription sales grew 57 percent year over year to 17 billion won ($12.4 million) in the first quarter of this year.According to drug statistics and information UBIST, seven products in the second-generation PPI series recorded negative growth
Viatris Korea celebrated 25 years of Lipitor (atorvastatin) sales in Korea, highlighting its pivotal role in dyslipidemia treatment and cardiovascular diseases (CVD) prevention at a press conference in Seoul on Wednesday.After its launch in 1997, Lipitor became the top-prescribed statin in Korea by
Chong Kun Dang said it has entered into a licensing agreement with Curigin, a local gene therapy developer, for the latter's CA102, a gene therapy candidate targeting superficial bladder cancer.Founded in 2016, Curigin has pioneered the development of siRNA technologies capable of suppressing multip
Attention is drawn to whether the reimbursement criteria for the multiple myeloma drug Darzalex (daratumumab), unchanged since May 2021, will be expanded for the first time in three years.Proposals to expand the reimbursement standard for the DVd (daratumumab/bortezomib/dexamethasone) and DKd (darat
Hanmi Pharmaceutical said it has entered into a clinical trial collaboration and supply agreement (CTCSA) with Merck & Co., Inc., known as MSD outside the U.S. and Canada.The partnership is set to advance the clinical research of Hanmi's dual-antibody therapy, BH3120, combined with MSD's immunothera
Pharos iBio said it has signed a memorandum of understanding with MEDiC Life Sciences, a Silicon Valley-based company that has established a gene-scissor technology (CRISPR) based cancer target and biomarker discovery platform, to collaborate on drug discovery.Through this agreement, the two compani
GC Biopharma said it has submitted an investigational new drug (IND) application and applied for Fast Track Designation with the U.S. FDA for GC1130A, an intracerebroventricular (ICV) enzyme replacement therapy (ERT) drug for Sanfilippo Syndrome Type A (MPS IIIA), jointly developed with Korean biote
Celltrion's Remsima (infliximab) line of products continues to demonstrate market impact with expanded prescriptions in five major European countries—the U.K., Germany, France, Spain, and Italy—also known as EU5.According to pharmaceutical market research firm IQVIA, as of the fourth quarter of 2023
HK inno.N's GERD drug K-CAB has expanded its momentum to the Middle East and North Africa region.Starting from China and expanding across Asia and North and South America, K-CAB is increasing its global market dominance by advancing to the Middle East and North Africa markets, according to the compa
Curocell, a chimeric antigen receptor-T (CAR-T) developer, has applied for Anbal-cel, its CAR-T candidate, to be included in the Ministry of Food and Drug Safety (MFDS)’s Advanced Biomedicine Expedited Approval System.The system is designed to facilitate the rapid market entry of innovative medicine